In 2023 and 2024, the stock market outperformed analyst expectations, with the S&P 500 index gaining over 20% in both years. However, these gains were largely concentrated in a narrow group of stocks, primarily within the technology sector.
Probability models suggest this upward trend could continue in 2025. Since 1926, the S&P 500 has delivered a positive annual return 73% of the time. And in 60% of those years, the index achieved double-digit growth.
The exciting news for investors is that 2025 may bring broader-based gains, indicating a return to widespread growth across sectors.
In this special presentation, we highlight seven stocks with the potential for 10% earnings growth over the next 12 months and forecasted share price increases of at least 20%. Our analysis spans multiple sectors, showcasing opportunities beyond the traditional market leaders. This broader perspective emphasizes the potential for diversified growth in the coming year.
Quick Links
- AbbVie
- Uber Technologies
- MercadoLibre
- Barrick Gold
- Cameco Corp.
- CAVA Group
- e.l.f. Beauty
#1 - AbbVie (NYSE:ABBV)
AbbVie Inc. (NYSE: ABBV) is frequently talked about as one of the best income stocks. That’s backed up by the company’s status as a Dividend King. But there are several reasons to believe that growth-oriented investors will want to take a closer look at this biopharmaceutical sector leader.
The company’s revenue and earnings were expected to take a hit after the patent expired on its blockbuster drug, Humira, in 2023. However, AbbVie has since launched drugs like Skyrizi and Rinvoq, which have helped mitigate the impact of lower Humira sales.
AbbVie already has a deep pipeline of drug candidates, but that didn’t stop the company from acquiring Nimble Therapeutics in December 2024, adding even more potential autoimmune drugs that it can bring to market.
Analysts project AbbVie to grow earnings at around 20%. If that’s accurate, ABBV stock is more likely to deliver a total return closer to its five-year average of around 28%.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
More- Current Price
- $189.97
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $208.35 (9.7% Upside)
#2 - Uber Technologies (NYSE:UBER)
You shouldn't think of Uber Technologies Inc. (NYSE: UBER) as a "forever stock." But if you’re looking for growth stocks that should outperform the market in the short term, the ridesharing leader is one to consider.
The bullish outlook for Uber hinges on its growing network effect. The company is seeing an increase in users on its platform, and those users are engaging more frequently over time.
In 2024, UBER stock was more of a trade than an investment, with a 58% swing between its 52-week high and low. Much of that uncertainty comes from the emergence of autonomous vehicle technology, which poses a significant long-term challenge for Uber’s business model.
While autonomous driving holds promise, analysts agree it remains several years from widespread adoption. For now, Uber offers strong growth potential. Analysts predict earnings growth of 33%, supporting a consensus price target of $91.53—a potential upside of over 34%.
About Uber Technologies
Uber Technologies, Inc develops and operates proprietary technology applications in the United States, Canada, Latin America, Europe, the Middle East, Africa, and Asia excluding China and Southeast Asia. It operates through three segments: Mobility, Delivery, and Freight. The Mobility segment connects consumers with a range of transportation modalities, such as ridesharing, carsharing, micromobility, rentals, public transit, taxis, and other modalities; and offers riders in a variety of vehicle types, as well as financial partnerships products and advertising services.
More- Current Price
- $69.71
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 32 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $90.89 (30.4% Upside)
#3 - MercadoLibre (NASDAQ:MELI)
If you’re willing to look outside the United States and a high price per share doesn’t bother you, MercadoLibre Inc. (NASDAQ: MELI) is a solid choice. Known as “the Amazon of Latin America," the company operates the region's largest e-commerce platform. Additionally, it boasts a robust fintech business that includes a credit card segment.
In 2024, MELI stock cracked the psychologically significant $2,000 per share mark before pulling back to end the year. This has kept analysts suggesting that the company may conduct a stock split. MercadoLibre has never split its stock, but it may do so if it feels it needs to make its share price more accessible.
MELI stock has delivered a total return of over 74% in the last three years, and analysts are forecasting 32% earnings growth, which should provide plenty of fuel for the stock to move higher.
About MercadoLibre
MercadoLibre, Inc operates online commerce platforms in the United States. It operates Mercado Libre Marketplace, an automated online commerce platform that enables businesses, merchants, and individuals to list merchandise and conduct sales and purchases digitally; and Mercado Pago FinTech platform, a financial technology solution platform, which facilitates transactions on and off its marketplaces by providing a mechanism that allows its users to send and receive payments online, as well as allows users to transfer money through their websites or on the apps.
More- Current Price
- $1,966.41
- Consensus Rating
- Buy
- Ratings Breakdown
- 16 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $2,244.69 (14.2% Upside)
#4 - Barrick Gold (NYSE:GOLD)
Gold was one of the best-performing asset classes of 2024, and many analysts believe this is just the beginning of a multi-year run. However, gold isn’t the only metal poised to shine in the coming years—copper is also expected to play a significant role.
That makes Barrick Gold (NYSE: GOLD) one of the growth stocks to watch closely. The Canadian company is one of the largest global miners of gold and copper.
Major miners like Barrick have the resources to develop large-scale, profitable projects. One such project is the Reko Diq copper and gold venture in Pakistan, a 50/50 joint venture in which the governments of Pakistan and the province of Balochistan own half the stake. When operations begin in 2028, Barrick estimates the project could generate $74 billion in free cash flow over the subsequent 37 years.
Mining stocks are notoriously cyclical, as Barrick’s historical stock price shows. However, analysts are forecasting earnings growth of over 30%, which is a bullish reason to own GOLD stock.
About Barrick Gold
Barrick Gold Corporation is a sector-leading gold and copper producer. Its shares trade on the New York Stock Exchange under the symbol GOLD and on the Toronto Stock Exchange under the symbol ABX.
In January 2019 Barrick merged with Randgold Resources and in July that year it combined its gold mines in Nevada, USA, with those of Newmont Corporation in a joint venture, Nevada Gold Mines, which is majority-owned and operated by Barrick.
More- Current Price
- $16.69
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 6 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $23.92 (43.3% Upside)
#5 - Cameco Corp. (NYSE:CCJ)
Cameco Corp. (NYSE: CCJ) offers investors a chance to capitalize on a key emerging trend for the next decade: the resurgence of nuclear energy. As the world's leading provider of uranium, Cameco stands to benefit from the growing recognition of nuclear power’s role in meeting clean energy goals. With increasing demand from the current electric grid and the energy-intensive needs of artificial intelligence (AI), nuclear energy's reliability and stability are becoming even more appealing.
In addition to its current reserves, the company is well-positioned with exploration projects that will contribute to future growth. Among those strategic investments is a 49% stake in Westinghouse, a nuclear plant technology company.
This strategic positioning supports positive cash flow, maintaining a strong balance sheet and enabling shareholder returns. Analysts project earnings growth of over 174%, with a consensus price target of $66.56, suggesting an 18% upside for the stock.
About Cameco
Cameco Corporation provides uranium for the generation of electricity. It operates through Uranium, Fuel Services, Westinghouse segments. The Uranium segment is involved in the exploration for, mining, and milling, purchase, and sale of uranium concentrate. The Fuel Services segment engages in the refining, conversion, and fabrication of uranium concentrate, as well as the purchase and sale of conversion services.
More- Current Price
- $50.30
- Consensus Rating
- Buy
- Ratings Breakdown
- 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $66.56 (32.3% Upside)
#6 - CAVA Group (NYSE:CAVA)
Fast-casual dining company CAVA Group Inc. (NYSE: CAVA) is leaning into an emerging trend that could cause its stock to outperform the S&P 500 in the coming years: growing consumer demand for healthy, fast-casual dining options that emphasize fresh, high-quality, and flavorful ingredients.
CAVA's Mediterranean-themed menu aligns perfectly with this trend, offering dishes like grain bowls, salads, and pita-based meals that emphasize vegetables, lean proteins, and Mediterranean flavors. CAVA competes with Sweetgreen Inc. (NYSE: SG) and Chipotle Mexican Grill Inc. (NYSE: CMG).
The company’s appeal is evident in its strong same-store sales growth and impressive average unit volumes. CAVA is also pursuing a deliberate expansion strategy. By the end of 2024, it operated approximately 350 locations, with plans to grow to around 1,000—and possibly more.
Since going public in 2023, CAVA has delivered a total return of 215%. Analysts are forecasting 22% earnings growth for CAVA in the next 12 months. They also give the stock a price target of $142.12, which offers investors a solid 15% growth.
About CAVA Group
CAVA Group, Inc owns and operates a chain of restaurants under the CAVA brand in the United States. The company also offers dips, spreads, and dressings through grocery stores. In addition, the company provides online and mobile ordering platforms. Cava Group, Inc was founded in 2006 and is headquartered in Washington, the District of Columbia.
- Current Price
- $142.53
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 8 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $142.13 (0.3% Downside)
#7 - e.l.f. Beauty (NYSE:ELF)
e.l.f. Beauty Inc. (NYSE: ELF) is a global cosmetics and skincare company that provides authentic and affordable products with low manufacturing costs, innovative marketing, and strong product innovation. The company's commitment to affordability and ethical business practices is a key reason why it’s attractive to the coveted Gen-Z demographic.
e.l.f. may focus on beauty, but it had an ugly stock chart in 2024. The stock had a 125% swing between its 52-week and low. That’s reflected in the company’s short interest. It’s only about 10%, but the number of shares shorted has grown about three times in the last year.
This price performance may be an example of the company’s stock getting ahead of its fundamentals. But that’s something that the company can grow into. Analysts believe that the company’s earnings will grow by 25%, and the consensus price target for ELF stock is $169.06, which is a 47% increase from the price in early 2025.
About e.l.f. Beauty
e.l.f. Beauty, Inc is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, WELL People and KEYS soulcare.
More- Current Price
- $88.43
- Consensus Rating
- Buy
- Ratings Breakdown
- 16 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $168.47 (90.5% Upside)
Investors hear many time-honored maxims like "time in the market beats timing the market." One that I like to keep in mind is "skate to where the puck is going."
There are two reasons for that. First, it's a good reminder that the growth stocks of five years ago may not be the same ones moving the market today. And second, investors frequently believe they need special knowledge to be successful at investing.
Let's be clear: you do have to put in the work. But the information you need to be a successful investor is not unknowable, even without a background in finance or accounting.
Sometimes, it helps to get a nudge in a particular direction. To select the stocks in this presentation, we used the MarketBeat Stock Screener, a free tool on MarketBeat.com, to narrow our search. And that's just one of the many research tools MarketBeat offers to keep you on top of the stocks you own or the ones on your watchlist
More Investing Slideshows: